Physician profile
Christopher Robert Behringer
NPI 1124521182
$2,622.39
in general payments reported to CMS, 2019-2025
27 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2022: $651 · 2023: $599 · 2024: $807 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.53 | 2022-2024 | Jardiance, Combivent Respimat, Stiolto Respimat |
| Novo Nordisk INC | $230.59 | 2021-2025 | Wegovy, Saxenda |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $222.56 | 2025 | Caplyta |
| Pfizer INC. | $221.49 | 2021-2024 | |
| Lilly USA, LLC | $214.55 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Mylan Specialty L.P. | $212.20 | 2022-2024 | Yupelri |
| Astellas Pharma US INC | $150.10 | 2022-2024 | Veozah, Myrbetriq |
| Amgen INC. | $148.67 | 2021-2024 | Prolia, Evenity, Otezla |
| Astrazeneca Pharmaceuticals LP | $122.78 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $84.48 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Ironwood Pharmaceuticals, INC | $81.02 | 2021-2024 | Linzess |
| Janssen Pharmaceuticals, INC | $73.60 | 2022-2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $68.38 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.05 | 2022-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $57.99 | 2022-2025 | Rexulti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $43.62 | 2021-2022 | |
| Abbvie INC. | $35.59 | 2023-2025 | Ubrelvy |
| Phathom Pharmaceuticals, INC. | $33.28 | 2024-2025 | Voquezna |
| Abbott Laboratories | $28.28 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $28.18 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $25.33 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $21.23 | 2022 | |
| Sumitomo Pharma America, INC. | $18.97 | 2025 | Myfembree |
| Axsome Therapeutics, INC. | $16.75 | 2024 | Auvelity |
| Amarin Pharma, INC. | $15.82 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.86 | 2022 | |
| Leo Pharma INC. | $11.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Behringer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.